JP2010047597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010047597A5 JP2010047597A5 JP2009242389A JP2009242389A JP2010047597A5 JP 2010047597 A5 JP2010047597 A5 JP 2010047597A5 JP 2009242389 A JP2009242389 A JP 2009242389A JP 2009242389 A JP2009242389 A JP 2009242389A JP 2010047597 A5 JP2010047597 A5 JP 2010047597A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- tumor
- associated antigen
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 93
- 108020004707 nucleic acids Proteins 0.000 claims 85
- 102000039446 nucleic acids Human genes 0.000 claims 85
- 206010028980 Neoplasm Diseases 0.000 claims 54
- 239000000427 antigen Substances 0.000 claims 54
- 102000036639 antigens Human genes 0.000 claims 54
- 108091007433 antigens Proteins 0.000 claims 54
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001875 tumorinhibitory effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10211088A DE10211088A1 (de) | 2002-03-13 | 2002-03-13 | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574831A Division JP4963778B2 (ja) | 2002-03-13 | 2003-03-12 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012213517A Division JP5711711B2 (ja) | 2002-03-13 | 2012-09-27 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010047597A JP2010047597A (ja) | 2010-03-04 |
| JP2010047597A5 true JP2010047597A5 (enExample) | 2011-01-20 |
Family
ID=27771250
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574831A Expired - Fee Related JP4963778B2 (ja) | 2002-03-13 | 2003-03-12 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2009242389A Pending JP2010047597A (ja) | 2002-03-13 | 2009-10-21 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2012213517A Expired - Lifetime JP5711711B2 (ja) | 2002-03-13 | 2012-09-27 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2012238202A Expired - Lifetime JP5756073B2 (ja) | 2002-03-13 | 2012-10-29 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2013041406A Expired - Lifetime JP5793158B2 (ja) | 2002-03-13 | 2013-03-04 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574831A Expired - Fee Related JP4963778B2 (ja) | 2002-03-13 | 2003-03-12 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012213517A Expired - Lifetime JP5711711B2 (ja) | 2002-03-13 | 2012-09-27 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2012238202A Expired - Lifetime JP5756073B2 (ja) | 2002-03-13 | 2012-10-29 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
| JP2013041406A Expired - Lifetime JP5793158B2 (ja) | 2002-03-13 | 2013-03-04 | 腫瘍において示差的に発現される遺伝子産物およびこの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US7429461B2 (enExample) |
| EP (18) | EP2277905A3 (enExample) |
| JP (5) | JP4963778B2 (enExample) |
| KR (4) | KR20110117735A (enExample) |
| CN (4) | CN105396144B (enExample) |
| AU (2) | AU2003219045B2 (enExample) |
| CA (3) | CA2813780C (enExample) |
| DE (1) | DE10211088A1 (enExample) |
| ES (3) | ES2559079T3 (enExample) |
| IL (4) | IL163900A0 (enExample) |
| MX (1) | MXPA04008867A (enExample) |
| NZ (1) | NZ535146A (enExample) |
| PL (1) | PL215160B1 (enExample) |
| WO (1) | WO2003076631A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| ATE519862T1 (de) * | 2002-08-20 | 2011-08-15 | Millennium Pharm Inc | Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs |
| DE10341812A1 (de) * | 2003-09-10 | 2005-04-07 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2015201737B2 (en) * | 2003-09-26 | 2016-09-15 | Biontech Ag | Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| DE10344799A1 (de) * | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102004023187A1 (de) * | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| JP5089173B2 (ja) * | 2005-01-07 | 2012-12-05 | 独立行政法人理化学研究所 | 一塩基多型を用いた炎症性疾患の判定方法 |
| DE102005013846A1 (de) * | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| ES2629749T3 (es) * | 2006-10-04 | 2017-08-14 | Dana-Farber Cancer Institute, Inc. | Inmunidad tumoral |
| EP2108701A1 (en) * | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| US11203783B2 (en) | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
| EA033478B1 (ru) | 2014-03-21 | 2019-10-31 | Haldor Topsoe As | Решетчатые модули без уплотнителей для подложки катализатора, а также модульная система подложки катализатора |
| SMT202400313T1 (it) | 2014-12-09 | 2024-09-16 | Regeneron Pharma | Animali non umani aventi un cluster umanizzato di un gene di differenziazione 274 |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| CN110734925B (zh) * | 2018-07-20 | 2023-04-07 | 上海市免疫学研究所 | 一种粒细胞或单核细胞标记系统及其标记方法和应用 |
| WO2021142349A1 (en) * | 2020-01-09 | 2021-07-15 | Deka Biosciences, Inc. | Method of using genetic markers, snps and/or indels to determine responsiveness to il-10 treatment |
| WO2024002537A1 (en) | 2022-06-30 | 2024-01-04 | Kmc Kartoffelmelcentralen Amba | Starch based gelatine replacement products |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0270056A1 (en) * | 1986-12-01 | 1988-06-08 | Northwestern University | Human LDH-C 4cDNA sequences encoding antigenic regions |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| AU1705397A (en) * | 1996-01-16 | 1997-08-11 | Northwestern University | Proteins and peptides for contraceptive vaccines and fertility diagnosis |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| JP2002503465A (ja) * | 1998-02-12 | 2002-02-05 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト受容体タンパク質 |
| CA2328128A1 (en) * | 1998-05-21 | 1999-11-25 | Diadexus Llc | A novel method of diagnosing, monitoring, and staging colon cancer |
| US6440663B1 (en) * | 1998-10-05 | 2002-08-27 | Ludwig Institute For Cancer Research | Renal cancer associated antigens and uses therefor |
| AU6181000A (en) * | 1999-07-29 | 2001-02-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel genes encoding protein kinase/protein phosphatase |
| WO2001009345A1 (en) * | 1999-07-29 | 2001-02-08 | Helix Research Institute | Novel genes encoding protein kinase/protein phosphatase |
| DE19936563A1 (de) * | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| CA2384713A1 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| AU2001229340A1 (en) * | 2000-01-14 | 2001-07-24 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU3087801A (en) * | 2000-02-04 | 2001-08-14 | Molecular Dynamics Inc | Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells |
| AU2001241541A1 (en) * | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU6802801A (en) * | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002010363A2 (en) * | 2000-07-28 | 2002-02-07 | Incyte Genomics, Inc. | Protein phosphatases |
| AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| AU2002253878A1 (en) * | 2001-01-25 | 2002-08-06 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
| WO2002078516A2 (en) | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US20040058341A1 (en) * | 2001-07-26 | 2004-03-25 | Y.Tom Tang | Protein phosphatases |
| KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| JP5565375B2 (ja) | 2011-05-12 | 2014-08-06 | 三菱電機株式会社 | 入退室管理装置 |
-
2002
- 2002-03-13 DE DE10211088A patent/DE10211088A1/de not_active Withdrawn
-
2003
- 2003-03-12 EP EP10010630A patent/EP2277905A3/de not_active Withdrawn
- 2003-03-12 IL IL16390003A patent/IL163900A0/xx unknown
- 2003-03-12 CA CA2813780A patent/CA2813780C/en not_active Expired - Lifetime
- 2003-03-12 CN CN201510846314.8A patent/CN105396144B/zh not_active Expired - Lifetime
- 2003-03-12 US US10/506,443 patent/US7429461B2/en not_active Expired - Lifetime
- 2003-03-12 ES ES03714811.1T patent/ES2559079T3/es not_active Expired - Lifetime
- 2003-03-12 CN CN201310025680.8A patent/CN103251952B/zh not_active Expired - Lifetime
- 2003-03-12 EP EP10010633.5A patent/EP2311860B1/de not_active Expired - Lifetime
- 2003-03-12 KR KR1020117024468A patent/KR20110117735A/ko not_active Abandoned
- 2003-03-12 EP EP10010629.3A patent/EP2289910B1/de not_active Expired - Lifetime
- 2003-03-12 EP EP10010626A patent/EP2277904A3/de not_active Withdrawn
- 2003-03-12 NZ NZ535146A patent/NZ535146A/en not_active IP Right Cessation
- 2003-03-12 PL PL373384A patent/PL215160B1/pl unknown
- 2003-03-12 EP EP10010635A patent/EP2314611A3/de not_active Withdrawn
- 2003-03-12 ES ES10010629.3T patent/ES2685053T3/es not_active Expired - Lifetime
- 2003-03-12 CN CNA038074931A patent/CN1646692A/zh active Granted
- 2003-03-12 EP EP10010639A patent/EP2332973A3/de not_active Withdrawn
- 2003-03-12 CN CN03807493.1A patent/CN1646692B/zh not_active Expired - Lifetime
- 2003-03-12 EP EP10010637A patent/EP2311862A3/de not_active Withdrawn
- 2003-03-12 CA CA3035543A patent/CA3035543C/en not_active Expired - Lifetime
- 2003-03-12 KR KR1020127025908A patent/KR20120127536A/ko not_active Ceased
- 2003-03-12 EP EP10010627A patent/EP2287181A3/de not_active Ceased
- 2003-03-12 EP EP10010624A patent/EP2277902A3/de not_active Withdrawn
- 2003-03-12 MX MXPA04008867A patent/MXPA04008867A/es active IP Right Grant
- 2003-03-12 CA CA2478413A patent/CA2478413C/en not_active Expired - Lifetime
- 2003-03-12 EP EP10010631A patent/EP2277906A3/de not_active Withdrawn
- 2003-03-12 EP EP10010625A patent/EP2277903A3/de not_active Withdrawn
- 2003-03-12 KR KR1020047014321A patent/KR101261887B1/ko not_active Expired - Lifetime
- 2003-03-12 EP EP10010634.3A patent/EP2314610B1/de not_active Expired - Lifetime
- 2003-03-12 EP EP10010623A patent/EP2277901A3/de not_active Withdrawn
- 2003-03-12 KR KR1020117004206A patent/KR20110026529A/ko not_active Ceased
- 2003-03-12 EP EP10010628.5A patent/EP2287182B1/de not_active Expired - Lifetime
- 2003-03-12 JP JP2003574831A patent/JP4963778B2/ja not_active Expired - Fee Related
- 2003-03-12 AU AU2003219045A patent/AU2003219045B2/en not_active Expired
- 2003-03-12 WO PCT/EP2003/002556 patent/WO2003076631A2/de not_active Ceased
- 2003-03-12 EP EP10010632A patent/EP2277907A3/de not_active Withdrawn
- 2003-03-12 ES ES10010628.5T patent/ES2688186T3/es not_active Expired - Lifetime
- 2003-03-12 EP EP03714811.1A patent/EP1483389B1/de not_active Expired - Lifetime
- 2003-03-12 EP EP10010636A patent/EP2311861A3/de not_active Withdrawn
- 2003-03-12 EP EP10010638A patent/EP2314612A3/de not_active Withdrawn
-
2004
- 2004-09-02 IL IL163900A patent/IL163900A/en active IP Right Grant
-
2008
- 2008-08-25 US US12/197,956 patent/US20090081214A1/en not_active Abandoned
- 2008-08-25 US US12/197,960 patent/US8716455B2/en not_active Expired - Lifetime
- 2008-12-16 AU AU2008258158A patent/AU2008258158A1/en not_active Abandoned
-
2009
- 2009-10-21 JP JP2009242389A patent/JP2010047597A/ja active Pending
-
2011
- 2011-07-18 US US13/184,719 patent/US8551490B2/en not_active Expired - Lifetime
-
2012
- 2012-09-27 JP JP2012213517A patent/JP5711711B2/ja not_active Expired - Lifetime
- 2012-10-29 JP JP2012238202A patent/JP5756073B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-04 JP JP2013041406A patent/JP5793158B2/ja not_active Expired - Lifetime
- 2013-03-12 US US13/796,094 patent/US9637794B2/en not_active Expired - Fee Related
-
2014
- 2014-05-02 US US14/268,160 patent/US9453260B2/en not_active Expired - Fee Related
- 2014-10-07 IL IL235085A patent/IL235085A/en active IP Right Grant
-
2015
- 2015-07-10 US US14/796,509 patent/US20160002738A1/en not_active Abandoned
-
2016
- 2016-03-14 IL IL244596A patent/IL244596A0/en unknown
- 2016-09-22 US US15/273,378 patent/US20170101479A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010047597A5 (enExample) | ||
| Lin et al. | Heterogeneity of HLA-G expression in cancers: facing the challenges | |
| JP2007537197A5 (enExample) | ||
| JP2007506417A5 (enExample) | ||
| JP2006516190A5 (enExample) | ||
| JP2008537546A5 (enExample) | ||
| JP5913547B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| Kato et al. | GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab | |
| Contreras et al. | Existence of CD8α-like dendritic cells with a conserved functional specialization and a common molecular signature in distant mammalian species | |
| JP5603145B2 (ja) | 疾患のイメージング、診断、及び治療 | |
| CN101044247B (zh) | 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法 | |
| JP2014239695A5 (enExample) | ||
| JP2008508861A5 (enExample) | ||
| US20150110714A1 (en) | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand | |
| JP2015525569A (ja) | 修飾型自己エピトープに対する抗腫瘍免疫応答 | |
| EP2523687A1 (en) | Methods for diagnosis and treatment of cutaneous t cell lymphomas | |
| CN114650842A (zh) | 抗tim-3抗体 | |
| JP2007526759A5 (enExample) | ||
| JP2011200233A5 (enExample) | ||
| EP1565571A2 (en) | Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll) | |
| CN109963865A (zh) | 用于检测和治疗肥大细胞活性相关病症的生物标记 | |
| US20240201192A1 (en) | Folr2+ macrophages and anti-tumor immunity | |
| CN116209479A (zh) | 癌症联合疗法 | |
| JP2012525121A5 (enExample) | ||
| JP2012525121A (ja) | 診断および治療のための腫瘍関連マーカーの同定 |